NEW DRUG APPROVALS by DR ANTHONY CRASTO

NEW DRUG APPROVALS  , my live blog on drugs and all u want to know

http://newdrugapprovals.wordpress.com/

...

..

DR ANTHONY MELVIN CRASTO Ph.D , Born in Mumbai in 1964 and graduated from Mumbai University, Completed his  PhD from ICT ,1991,  Mumbai, India in Organic chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues,

Currently he is working with GLENMARK- GENERICS LTD, Research centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India.

Prior to joining Glenmark, he worked with major multinationals like Hoechst Marion Roussel, now Sanofi Aventis,  & Searle India ltd, now Rpg lifesciences, etc. He has worked in Basic research, Neutraceuticals, Natural products, Flavors, Fragrances, Pheromones, Vet Drugs, Drugs, formulation, GMP etc. He has total 25 yrs exp in this field, he is now helping millions, has million hits on google on all organic chemistry websites.

His New Drug Approvals ,  Green Chemistry International,  Eurekamoments in Organic Chemistry ,  Organic Chemistry by Dr Anthony,  WIX BLOG , are some most read chemistry blogs

He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 25 year tenure, good knowledge of IPM, GMP, Regulatory aspects, he has  several international drug patents published worldwide .

He has good proficiency in Technology Transfer, Spectroscopy , Stereochemistry , Synthesis, Reactions in Org Chem , Polymorphism,  Pharmaceuticals , Medicinal chemistry , Organic chemistry literature , Patent related site , Green chemistry , Reagents , R & D , Molecules , Heterocyclic chem , Sourcing   etc

He suffered a paralytic stroke in dec 2007 and is bound to a wheelchair, this seems to have injected feul in him to help chemists around the world, he is more active than before and is pushing boundaries, he has one lakh connections on all networking sites, He makes himself available to all, contact him on  +91 9323115463, amcrasto@gmail.com

call +91  9323115463  india

THANKS AND REGARD’S
DR ANTHONY MELVIN CRASTO Ph.D

amcrasto@gmail.com

MOBILE-+91 9323115463

GLENMARK SCIENTIST , NAVIMUMBAI, INDIA
web link

http://about.me/amcrasto
http://anthonymelvincrasto.brandyourself.com/

http://amcrasto.bravesites.com/
http://amcrasto.theeurekamoments.com/

http://anthonycrasto.jimdo.com/
http://www.anthonymelvincrasto.yolasite.com/
http://www.slidestaxx.com/anthony-melvin-crasto-phd

https://sites.google.com/site/anthonycrastoorganicchemistry/sites—my-own-on-the-net

http://amcrasto.biz.ly/

http://anthonycrasto.wordpress.com/

http://organicchemistrysite.blogspot.com/

http://www.mendeley.com/profiles/anthony-melvin-crasto/

http://amcrasto.wix.com/anthony-melvin-crasto/apps/blog
Congratulations! Your presentation titled “Anthony Crasto Glenmark scientist, helping millions with websites” has just crossed MILLION views.

アンソニー     安东尼   Энтони    안토니     نتوني

join my process development group on google

organic-process-development group

you can post articles and will be administered by me on the google group which is very popular across the world

https://sites.google.com/site/anthonycrastomycv/cv

http://www.epernicus.com/amc10

http://scipeople.com/users/87574341/

https://sites.google.com/site/amcrasto/

http://www.skillpages.com/organic-chemist/thane-india/anthony-melvin.crasto

http://amcrasto.mixxt.com

http://join.apnacircle.com/?sponsor=anthony-melvin.crasto-ph.d&lang=en
LinkedIn group SYNTHETIC ORGANIC CHEMISTRY

ORGANIC CHEMISTRY SITE
JOIN COMMUNITY ON GOOGLE PLUS
http://amcrasto.webs.com/
http://newdrugapprovals.wordpress.com/

Pictures from an organic chemistry laboratory by Kristoff

 

by
-Kristof
http://labphoto.tumblr.com/
Pictures from an organic chemistry laboratory
All of these pictures are taken by  kristoff, he own all rights and please write if you want to use them somewhere. Thanks!
-Kristof
http://labphoto.tumblr.com/  see more by kristof

ARAB MEDICINE

 
LINK IS
http://newdrugapprovals.wordpress.com/2013/04/18/arab-medicine-review/

AYURVEDA –DIABETES and MEDICINAL HERBS

 

LINK IS
http://newdrugapprovals.wordpress.com/2013/04/15/ayurveda-diabetes-and-medicinal-herbs/

READ A FULL POST WRITTEN BY ME ON ABOVE LINK
 DR A.M.CRASTO

New drug approvals blog, Worlddrugtracker

15000 view across 107 countries in two and half months
My blog on new drug approvals is going strong
link

http://newdrugapprovals.wordpress.com/

This gives me status of worlddrugtracker
thanks

Drug spotlight- Icatibant, FDA 2011

Icatibant (trade name Firazyr) is a peptidomimetic drug consisting of ten amino acids, which is a selective and specific antagonist of bradykinin B2 receptors. It has been approved by the European Commission for the symptomatic treatment of acute attacks,^[1][2] of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

Bradykinin is a peptide-based hormone that is formed locally in tissues, very often in response to a trauma. It increases vessel permeability, dilates blood vessels

and causes smooth muscle cells to contract . Bradykinin plays an important role as the mediator of pain. Surplus bradykinin is responsible for the typical symptoms of inflammation, such as swelling, redness, overheating and pain. These symptoms are mediated by activation of bradykinin B2 receptors. Icatibant acts as a bradykinin inhibitor by blocking the binding of native bradykinin to the bradykinin B2 receptor.

Icatibant has received orphan drug status in Australia, EU, Switzerland and US.

In the EU, the approval by the European Commission (July 2008) allows Jerini to market Firazyr in the European Union's 27 member states, as well as Switzerland, Lichtenstein and Iceland, making it the first product to be approved in all EU countries for the treatment of HAE.^[1] In the US, the drug was granted FDA approval on August 25, 2011.^[3]

1.      1 "Jerini Receives European Commission Approval for Firazyr (Icatibant) in the Treatment of HAE" (Press release). Jerini AG. 2008-07-15. Retrieved 2008-07-22.

2.       2 "Jerini Receives Positive CHMP Opinion Recommending European Approval for Icatibant in the Treatment of HAE; FDA Issues Not Approvable Letter" (Press release).Jerini AG. 2008-04-24. Retrieved 2008-07-22.

3.      3 FDA Approves Shire’s FIRAZYR (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)" (Press release). Shire. Retrieved 2011-08-28.

On the August 25th 2011, the FDA approved Icatibant (trade name: Firazyr^TM), a bradykinin B2 receptor (B2R) antagonist indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients aged 18 or older.

HAE is a rare genetic disease and is caused by low levels of C1-esterase inhibitor (C1-INH), the major endogenous inhibitor and regulator of the protease plasma kallikrein and the key regulator of the Factor XII/kallikrein cascade. One component this cascade is the production of bradykinin by plasma kallikrein. During HAE attacks, disregulated activity of plasma kallikrein leads to excessive bradykinin production; bradykinin is a potent vasodilator, which s thought to be responsible for the characteristic HAE symptoms of localised swelling, inflammation and pain.

Icatibant treats the clinical symptoms of HAE attack by selective- and competitively binding, as an antagonist, to the B2 bradykinin receptor (B2R) , with similar affinity to bradykinin (1-10 nM for the B2R, while affinity for the B1R is 100-fold lower). Icatibant is the first in class agent against this target. The -tibant stem covers bradykinin antagonists.

B2R is a Rhodopsin-like receptor, 391 amino acid long, which belongs to the G protein-coupled receptor (GPCR) A3 family and is encoded by the BDKRB2 gene in humans. The amino acid sequence of B2R is:

>B2R

---

MFSPWKISMFLSVREDSVPTTASFSADMLNVTLQGPTLNGTFAQSKCPQVEWLGWLNTIQ

PPFLWVLFVLATLENIFVLSVFCLHKSSCTVAEIYLGNLAAADLILACGLPFWAITISNN

FDWLFGETLCRVVNAIISMNLYSSICFLMLVSIDRYLALVKTMSMGRMRGVRWAKLYSLV

IWGCTLLLSSPMLVFRTMKEYSDEGHNVTACVISYPSLIWEVFTNMLLNVVGFLLPLSVI

TFCTMQIMQVLRNNEMQKFKEIQTERRATVLVLVVLLLFIICWLPFQISTFLDTLHRLGI

LSSCQDERIIDVITQIASFMAYSNSCLNPLVYVIVGKRFRKKSWEVYQGVCQKGGCRSEP

IQMENSMGTLRTSISVERQIHKLQDWAGSRQ